Pneumonia Market and Epidemiology Insights 2018-2023 and Outlook 2024-2034 - Featuring Allergan/Pfizer, Merck Sharp and Dohme, Shionogi, Paratek Pharma, Nabriva Therapeutics, and More [Yah...
Eagle Pharmaceuticals, Inc. (EGRX)
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.eagleus.com
Company Research
Source: Yahoo! Finance
The 7 major pneumonia markets are expected to exhibit a CAGR of 5.32% during 2023-2034. The pneumonia market has been comprehensively analyzed in this report titled "Pneumonia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pneumonia is an infection that causes swelling and fluid or pus buildup in the alveoli (air sacs) of one or both lungs. It may range from moderate to severe and affect people of all ages, but it is most dangerous for older adults, infants, and those with a weakened immune system. The common symptoms of the ailment include coughing with phlegm or pus, fever, chills, difficulty breathing, chest pain, vomiting, nausea, loss of appetite, fatigue, confusion, etc. In severe cases, individuals suffering from this illness may also experience increased heart rate, palpitations, body pain, as well as bluish lips or nails. The diagnosis of pneumonia typically involves a combination of medical history, physical examination,
Show less
Read more
Impact Snapshot
Event Time:
EGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EGRX alerts
High impacting Eagle Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EGRX
News
- Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), Driven Brands Holdings Inc. (NASDAQ:DRVN), Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), and Gristone bio, Inc. (NASDAQ:GRTS)Accesswire
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq [Yahoo! Finance]Yahoo! Finance
EGRX
Earnings
- 8/8/23 - Beat
EGRX
Sec Filings
- 5/29/24 - Form 8-K
- 5/22/24 - Form 8-K
- 5/15/24 - Form 8-K
- EGRX's page on the SEC website